Brabant Pharma is a biotechnology and healthcare startup that focuses on pioneering hope for children with Dravet Syndrome through exceptional oral treatment. Their flagship product, Brabafen, is specifically designed for children suffering from this severe childhood epilepsy, known for causing catastrophic seizures and significant cognitive impairment. With a mortality rate of 10%-15% among affected children, the syndrome has proven resistant to conventional anticonvulsants.
Founded in 2013, Brabant Pharma has exclusive rights to utilize 20 years of clinical data, demonstrating exceptional efficacy in treating children with Dravet Syndrome. The rarity of this condition positions Brabafen to qualify as an Orphan Product in both Europe and the United States, providing data exclusivity for 10 and 7 years, respectively.
The last investment in Brabant Pharma was a Venture Round investment on 08 March 2013, led by Aquarius Equity Partners. This indicates a promising trajectory for the startup, as it continues to make significant strides in addressing the unmet medical needs of children with Dravet Syndrome.
